Vipul Ganatra, MD
Infectious Disease · Phoenix, AZNPI 1093769689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $128,510 of the $151,193 with a category attached, or 85.0%. AbbVie accounts for 78.8% of it on its own, with 10 other manufacturers making up the rest. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $459.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$119K
- Merck$18K
- Shionogi Inc$7K
- Paratek Pharmaceuticals, Inc.$5K
- Astellas Pharma US Inc$906
- Melinta Therapeutics, LLC$287
- plus $460 from 5 others
What the payments were for
- Consulting fees$6,5934%
- Speaking & faculty fees$128,51085%
- Travel & lodging$5,9204%
- Food & beverage$9,1606%
- Education$1,0101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 253 | $119,159 |
| Merck | 28 | $18,155 |
| Shionogi Inc | 10 | $6,736 |
| Paratek Pharmaceuticals, Inc. | 12 | $5,490 |
| Astellas Pharma US Inc | 11 | $906 |
| Melinta Therapeutics, LLC | 6 | $287 |
| Abbott | 1 | $164 |
| Insmed, Inc. | 1 | $133 |
| Recordati_rare_diseases_inc. | 4 | $86 |
| Smith+Nephew | 2 | $51 |
| ETS Wound Care LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,193 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 12 | $3,961 |
| CeftriaxoneCeftriaxone Sodium | 15 | $301 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Phoenix
- Thanes VanigPhoenix$258K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Ngozi OsonduPhoenix$5K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
- Edwin YuPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.